AI is a viable alternative to high throughput screening: a 318-target study

: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery

Driving multisectoral antimicrobial resistance action in South America: Lessons learned from implementing an enhanced tripartite AMR country self-assessment tool

As part of an innovative Tripartite-EU collaboration Project that supports seven South American countries, a Landscape Analysis Tool (LAT) was developed and implemented to collect data to complement the Tripartite AMR Country Self-Assessment Survey (TrACSS) process. The LAT enables collection of broader and deeper information to guide development of priority One Health activities, and strengthen national action plans to combat antimicrobial resistance. The Project developed the tool, trained a consultant pool in its use, and implemented it in conjunction with multi-sectoral country teams. The main results were seven priority-informed country workplans that proposed specific activities in line with the Strategic Objectives of each country's national action plan. LAT implementation clearly showed that the tool is a strong complement to the TrACSS process and that there can be considerable benefit to the process of collecting additional data layers, especially to strengthen country ownership of AMR-related information and solidifying multisectoral engagement. Countries elsewhere might consider implementing this complementary tool – either once to establish a baseline – or periodically to gain a better ongoing understanding of the situation on the ground

Options. Journal of the UNAB Financial Engineering Program. Volume 3 No. 6 December 2009

El programa de Ingeniería Financiera enfrenta importantes retos para el 2010, enmarcados en disposiciones y lineamientos que en materia educativa disponen el Estado y la Institución, principalmente, que sumados a expectativas y exigencias de la comunidad, integrada por estudiantes, egresados, empresarios, otras instituciones educativas y relacionados en general, harán necesarias la caracterización de programas de alta calidad y de amplio reconocimiento nacional e internacional. Para ello es indispensable la disposición de estrategias y proyectos específicos que apunten al logro de altos Índices de calidad en cada programa.Editorial. - 5 Generalidades de la administración del riesgo. - 7 Uso de las redes neuronales en la medición del riesgo de crédito. - 21 Teoría del valor extremo, aplicación a índices bursátiles de dos economías: Emergente y desarrollada. - 27 Ingenieros financieros como constructores de la sociedad: emprendimiento e intraemprendimiento. - 35 Determinantes del spread bid-ask de las opciones call y put sobre el Índice Dow-Jones. - 42 Las leyes del servicio o los principios fundamentales. 50The Financial Engineering program faces important challenges for 2010, framed in provisions and guidelines that the State and the Institution have in educational matters, mainly, which added to the expectations and demands of the community, made up of students, graduates, businessmen, other institutions educational and related in general, will make it necessary to characterize high-quality programs with wide national and international recognition. For this, it is essential to have specific strategies and projects aimed at achieving high quality indices in each program

XIV Jornada de Investigación 2023

Eje temático I: derecho, cultura y sociedad: En este eje tamático, se presentan ponencias que tienen como propósito analizar y explicar críticamente, a través de la investigación científica y desde el enfoque interdisciplinar, los derechos humanos, el proceso de estructuración de La convivencia y la equidad en la vivencia de los derechos; los valores, las costumbres, las normas, los estilos de vida, el uso de artefactos y la organización social; los procesos de desarrollo espiritual, de conocimiento científico, de desarrollo tecnológico y estético, y la convivencia y sus implicaciones en lo público y lo privado. Eje temático II: desarrollo humano y sostenible. El segundo eje temático que abordó la XII Jornada de Investigación fue desarrollo humano y sostenible, con ponencias que abarcaron todos aquellos aspectos que van, desde el desarrollo y bienestar individual, pasando por los estudios de las comunidades, para llegar a una comprensión global de la sostenibilidad como un factor determinante de existencia de las sociedades. Eje temático III: gestión y tecnología al servicio de la sociedad. Finalmente, en la XII Jornada de Investigación, se trabajóel eje temático gestión y tecnología al servicio de la sociedad, en el cual se presentaron, desde las diferentes disciplinas, ponencias que aportaron al campo del desarrollo productivo y a la solución de los problemas de la sociedad a través de las oportunidades que una buena gestión y un apropiado uso de la tecnología ofrece. (Tomado de la Fuente)EJE TEMÁTICO I: DERECHO, CULTURA Y SOCIEDAD La respuesta económica a la pandemia dentro del Estado social de derecho colombiano. Los espacios intermediarios como contenedores de experiencias significativas. Análisis del estilo lingüístico aplicado a la psicología jurídica. ¿Dejar o transformar? Cinco puntos para entender la ciudad contemporánea. Studiositas y verdad en la educación centrada en la persona. Los derechos de autor en el contrato de trabajo y de prestación de servicios. Afectación de los derechos sexuales reproductivos femeninos durante el conflicto armado en Colombia. Problemas del acceso a la justicia del campesinado de los páramos de Sumapaz y Santurbán. Vulneración del derecho al agua potable en La Guajira: una falta de garantías. Derechos humanos e inteligencia militar: el dilema de la primacía del interés general sobre el particular. Cuantificación del dolor humano por parte de la justicia colombiana. Retos tecnológicos en el derecho vs. Limitaciones en Colombia en las poblaciones más vulnerables. Construir identidad territorial a través del corredor socioambiental Los Nevados. La naturaleza en la arquitectura: una mirada a la arquitectura del siglo XX. Contrato de trabajo del futbolista profesional. La baja educación en las zonas rurales por consecuencia del conflicto armado y la corrupción en el Estado colombiano. Incidentes de la migración venezolana en el ámbito normativo nacional colombiano e internacional. Legalización definitiva del consumo adulto del cannabis en Colombia: un debate jurídico y constitucional. Wawamia jai, síndrome propio de la cultura: una caracterización de los signos y síntomas de una enfermedad cultural del pueblo indígena emberá-katío. La cruda realidad del reclutamiento de niños, niñas y adolescentes en el conflicto armado en Colombia: una visión nacional e internacional. EJE TEMÁTICO II: DESARROLLO HUMANO Y SOSTENIBLE Migración venezolana en Colombia: perspectiva crítica sobre el derecho de acceso a la salud. El estrés laboral. Una imagen no es tradición: la actualidad de la vivienda raizal en el Archipiélago de San Andrés, Providencia y Santa Catalina. Aprendizajes del proceso de diseño basado en la investigación: caso de estudio barrio Concepción Norte, Bogotá, Colombia. Sumapaz como territorio potencial hídrico y patrimonio paisajístico y cultural: modelo de región sostenible. Revisión sistemática del liderazgo digital desde las competencias digitales. Intervenciones psicológicas basadas en evidencia: tendencias actuales. Herramientas pedagógicas para la concientización de la comunidad a partir del reconocimiento de la memoria histórica en el barrio San Benito, Bogotá, Colombia. Diseño sostenible como factor diferencial en la reconversión industrial de las curtiembres en el barrio San Benito, Bogotá, Colombia. Motivación escolar como factor relacionado con el rendimiento académico en estudiantes en extraedad en la Institución Educativa Distrital República de México, sede B, jornada mañana. La realidad de los objetos artificiales. Performance en nuestro diario vivir. ¿Es necesario la modificación del lugar para satisfacer las necesidades del ser humano? ¿Es necesario hacer modificaciones al espacio natural para generar cultura? La arquitectura como síntesis entre los objetos con propósito o sin él. La creación de los objetos y sus impactos en el mundo. ¿Cuáles son los determinantes de las brechas de competencia laboral en el departamento de Cundinamarca, Colombia? Buenas prácticas de habitabilidad. Reconocimiento de la arquitectura doméstica tradicional en Colombia como una pauta de identidad para el diseño de nuevas viviendas. Validación de un instrumento para evaluar la procrastinación académica. Escala de medición de la soledad BATAN. Contraste entre el instrumento para medir la resiliencia en adultos jóvenes de Colombia (CLANP) con CD-RISC 10. Finlandia y naturaleza: país modelo en ratificación de normas y tratados para la protección de los derechos de la naturaleza. EJE TEMÁTICO III: GESTIÓN Y TECNOLOGÍA AL SERVICIO DE LA SOCIEDAD Aplicación de una tecnología limpia desde el diseño resiliente: simulación de un módulo básico de vivienda social en la ciudad de Tunja, Colombia. Recorrido virtual de la Universidad Católica de Colombia Sede Claustro para la inducción de estudiantes y docentes. Evaluación de eficiencia de un prototipo de un sistema de atrapanieblas tipo NRP 3.0 para la vereda Gaunza Arriba, municipio de Guateque, departamento de Boyacá, Colombia. Sistema de Información para la Coordinación de Trabajos de Grado del Programa de Ingeniería de Sistemas de la Universidad Católica de Colombia (SIGETG). Estrategias de sostenibilidad para la reducción de la huella hídrica en la vivienda de la Costa Caribe. Sistema de evaluación de resultados de aprendizaje de la Facultad de Psicología de la Universidad Católica de Colombia. Identificación de tendencias en la implementación de DevOps a partir de una revisión sistemática. Desarrollo de un algoritmo de trading para operar el mercado de divisas a través de ondas de Elliott y números de Fibonacci. Los derechos humanos en el espacio de la inteligencia artificial. Construcción de paz a través del ciberactivismo en redes sociales de cuatro organizaciones juveniles de Bogotá. Las redes sociales digitales como herramienta educativa: una propuesta de investigación-innovación. Videojuego de realidad virtual sobre la extracción y el tráfico ilegal de la fauna silvestre en Colombia. Arquitectura de la información de la plataforma de inteligencia artificial para el estudio neurocognitivo y el apoyo a la salud mental. Inmersión sobre la innovación: perspectivas sobre el derecho al trabajo y la inteligencia artificial en el servicio de justicia. El ciberterrorismo en la legislación colombiana: un análisis desde la criminología. Modelo de fabricación digital de diseño sostenible para vivienda social. Uso de los videojuegos en el campo educativo: ventajas y desventajas. Resolución electrónica de controversias en procesos civiles de mínima cuantía en Colombia. Estrategia de evaluación y promoción de la salud mental en el contexto universitario. Caracterización de técnicas y herramientas de inteligencia artificial utilizadas para el perfilamiento de clientes por las mipymes en Colombia. Transformar el casco urbano del municipio de Líbano, departamento del Tolima, Colombia: un proyecto parque industrial para el intercambio de saberes y revitalización ambiental. Aplicación tecnológica en agricultura urbana para promover la seguridad alimentaria en poblaciones vulnerables. CONCLUSIONE

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

BackgroundSparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis.MethodsPROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin–angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850.FindingsBetween Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (−42·8%, 95% CI −49·8 to −35·0, with sparsentan versus −4·4%, −15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals.InterpretationOver 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis. Methods PROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin–angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850. Findings Between Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (−42·8%, 95% CI −49·8 to −35·0, with sparsentan versus −4·4%, −15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals. Interpretation Over 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function.</p

Stress neuropeptide levels in adults with chest pain due to coronary artery disease: potential implications for clinical assessment

: Substance P (SP) and neuropeptide Y (NPY) are neuropeptides involved in nociception. The study of biochemical markers of pain in communicating critically ill coronary patients may provide insight for pain assessment and management in critical care. Purpose of the study was to to explore potential associations between plasma neuropeptide levels and reported pain intensity in coronary critical care adults, in order to test the reliability of SP measurements for objective pain assessment in critical care